Joel Parker
University of North Carolina at Chapel Hill
H-index: 142
North America-United States
Top articles of Joel Parker
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation (vol 22, pg 632, 2016) | Nature medicine | George P Souroullas William R Jeck Joel S Parker Jeremy M Simon Jie-Yu Liu | 2016/6 |
Abstract PO2-15-07: HER2DX genomic assay in triple-negative breast cancer (TNBC) patients treated with 12-weeks of neoadjuvant chemotherapy: a correlative analysis from WSG … | Cancer Research | Oleg Gluz Fara Brasó-Maristany Ulrike Nitz Laia Paré Matthias Christgen | 2024/5/2 |
DNA Copy Number Alterations (CNAs) to Determine Cancer Phenotypes | 2024/1/18 | ||
Abstract PO2-15-06: ctDNA-based DNADX in hormone receptor-positive and HER2-negative (HR+/HER2-) advanced breast cancer following endocrine therapy and CDK4/6 inhibition: a … | Cancer Research | Fara Brasó-Maristany Javier Cortés José Manuel Pérez-García Rosario Vega-León Laia Paré | 2024/5/2 |
Abstract PO2-15-08: Exploring Essential Immune Genes Linked to Pathological Complete Response and Survival in Early-Stage Triple-Negative Breast Cancer (TNBC) after … | Cancer Research | Fara Brasó-Maristany Laia Paré Benedetta Conte Laura Angelats Ana Vivancos | 2024/5/2 |
Abstract PO3-16-03: Investigating HER2DX genomic assay concordance within HER2-positive breast cancer | Cancer Research | Fara Brasó-Maristany Laia Paré Guillermo Villacampa Mercedes Marín-Aguilera Paul Spellman | 2024/5/2 |
The VEGF-Hypoxia Signature Is Upregulated in Basal-like Breast Tumors from Women of African Ancestry and Associated with Poor Outcomes in Breast Cancer | Clinical Cancer Research | Yoo Jane Han Siyao Liu Ashley Hardeman Padma Sheila Rajagopal Jeffrey Mueller | 2024/5/1 |
Methylation markers for melanoma and uses thereof | 2023/8/31 | ||
Abstract P6-01-46: Independent validation of the HER2DX genomic test in HER2-positive breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab+/-pertuzumab … | Cancer Research | Coralia Bueno-Muiño Isabel Echavarria Sara López-Tarruella Roche-Molina Marta María del Monte-Millán | 2023/3/1 |
Calorie restriction outperforms bariatric surgery in a murine model of obesity and triple-negative breast cancer | JCI insight | Kristina K Camp Michael F Coleman Tori L McFarlane Steven S Doerstling Subreen A Khatib | 2023/10/10 |
Determining the regulatory logic of breast cancer cells using single-cell multi-omics | Cancer Research | Matthew J Regner Aatish Thennavan Susana Garcia-Recio Kamila Wisniewska Philip M Spanheimer | 2023/4/4 |
Assessment of the HER2DX assay in patients with ERBB2-positive breast cancer treated with neoadjuvant paclitaxel, trastuzumab, and pertuzumab | JAMA oncology | Adrienne G Waks Esther R Ogayo Laia Paré Mercedes Marín-Aguilera Fara Brasó-Maristany | 2023/6/1 |
Nano46 genes and methods to predict breast cancer outcome | 2023/8/31 | ||
Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer | Nature communications | Aleix Prat Fara Brasó-Maristany Olga Martínez-Sáez Esther Sanfeliu Youli Xia | 2023/3/1 |
Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727) | Clinical Cancer Research | Holly Tovey Orsolya Sipos Joel S Parker Katherine A Hoadley Jelmar Quist | 2023/9/15 |
Pre-treatment differential correlation of gene expression and response to topical steroids in eosinophilic esophagitis | Diseases of the Esophagus | Evan S Dellon Yihsuan S Tsai Alisha R Coffey Kelly Bodwin Jared A Sninsky | 2023/4 |
An integrated model for predicting KRAS dependency | PLoS computational biology | Yihsuan S Tsai Yogitha S Chareddy Brandon A Price Joel S Parker Chad V Pecot | 2023/5/4 |
Gene expression profiles to predict breast cancer outcomes | 2023/8/10 | ||
HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1 | JNCI: Journal of the National Cancer Institute | Fara Brasó-Maristany Gaia Griguolo Nuria Chic Tomás Pascual Laia Paré | 2023/3/1 |
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes (Reprinted from vol 27, pg 1160, 2009) | JOURNAL OF CLINICAL ONCOLOGY | Joel S Parker Michael Mullins Maggie CU Cheang Samuel Leung David Voduc | 2023/9/10 |
